Levosimendan (INN) / ˌliːvoʊsaɪˈmɛndən / is a calcium sensitizer used in the management of acutely decompensated congestive heart failure. It is marketed under the trade name Simdax (Orion Corporation). Overall the drug has a two fold mechanism of action.

Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate.

2024年7月13日 · stabilises troponin C in a conformation that triggers and maintain contraction. -> reduces preload, afterload, improves O2 supply to myocardium, increases coronary blood flow and renal blood flow. increases: Q, SV, HR and coronary blood flow. decreases: SVR, SBP, PCWP, PAP, coronary vascular resistance, myocardial oxygen consumption.

In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitisation and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the Eu...

Levosimendan is a calcium sensitizer indicated to treat acutely decompensated severe chronic heart failure. Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels.

Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate.

Levosimendan is an inodilator drug that, given its unique pharmacological actions and safety profile, represents a viable therapeutic option in patients with heart failure with reduced ejection fraction in the advanced stage of the disease (advHFrEF).